VG-3927

TargetTREM2

Modalitysmall molecule agonist

IndicationAlzheimer's disease

PhasePhase 1 (Completed)

PartnerNone

Trial IDNCT06343636

Registry statusCOMPLETEDVerified 2026-10-05

Notes

VG-3927 is a highly brain-penetrant small-molecule TREM2 agonist designed to activate microglia in Alzheimer's disease. Its Phase 1 study in healthy adults and participants with Alzheimer's disease is complete.

Source

Program entries are factual summaries of publicly disclosed clinical programs. Microglia.ai does not imply predictions about therapeutic outcomes or investment advice.

Last reviewed: October 5, 2026